Illumina $7.1B deal for Grail sent back to FTC by appeals court
Sundry Photography/iStock Editorial via Getty Images Illumina's (NASDAQ:ILMN) planned $7.1 billion purchase of cancer test developer Grail was sent back to the Federal Trade Commission by a U.S. appeals court, who still determined that…
